PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

EHA2022 Hybrid Congress

June 9-12 Vienna

N. Poster

Poster title

Applicant name

Status


306-P	PAX5 DEFICIENCY AND GERMLINE SUSCEPTIBILITY TO PEDIATRIC LEUKEMIA	Franziska Auer	Received

307-P	DEL(17)(Q11) IS TYPICAL MARKER OF IMMATURE T-ALL OF ADULTS, WITH NF1, UTP6, AND SUZ12 HAPLOINSUFFICIENCY, GENOME INSTABILITY, AND GENE DOWNREGULATION	Valentina Bardelli	Received

310-P	BH3 PROFILING IDENTIFIES SELECTIVE BCL-2 DEPENDENCE OF ADULT EARLY T-CCELL PROGENITOR AND TYPICAL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Shruti Bhatt	Received

313-P	RECURRENT PATHOGENIC GERMLINE CHEK2 VARIANTS IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES	Triantafyllia Brozou	Received

314-P	THERAPEUTICALLY TARGETING THE UNIQUE BARCODE OF MLL/AF4	Rachel Cameron	Received

316-P	THE ROLE OF TET2 IN (PRE)-LEUKEMIC T-ALL: TET2 TO THE RESCUE?	Stien De Coninck	Received

317-P	TARGETING HYPERACTIVE PDGFR-B IN T-ALL AND T-LBL	Stien De Coninck	Received

318-P	A DUAL ROLE FOR PSIP1 IN T-ALL	Lisa Demoen	Received

320-P	TCF3-PBX1 LEUKEMIA INVADES IPSC-DERIVED CEREBRAL ORGANOIDS	Philip Gebing	Received

324-P	PHARMACOLOGIC INHIBITION OF DYRK1A RENDERS HIGH-RISK KMT2A-R ALL SENSITIVE TO VENETOCLAX	Christian Hurtz	Received

333-P	MULTI-COHORT GENE EXPRESSION RESOURCE FOR AUTOMATIC SUBTYPING OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Ville-Petteri Mäkinen	Received

337-P	LONG TERM INFECTION-DRIVES CHANGES IN THE BONE MARROW MICRO-ENVIRONMENT OF PAX5+/- MICE PREDISPOSED TO B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA	Aleksandra Pandyra	Received

340-P	IN VITRO AND IN VIVO EFFICACY OF A NOVEL KINASE INHIBITOR TARGETING JAK2 GENE REARRANGEMENTS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA	Manuel Quadri	Received

344-P	THE DUAL BCL-2 AND BCL-XL INHIBITOR AZD4320 SHOWS ON-TARGET ACTIVITY IN ALL AND ACTS SYNERGISTICALLY WITH MCL-1 INHIBITION	Felix Seyfried	Received

347-P	COOPERATION OF TLX3 AND FLT3-ITD IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IS ENHANCED BY TLE4 INACTIVATION	Quentin Van Thillo	Received

348-P	MRK-560 AND DEXAMETHASONE ARE SYNERGISTIC IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Charlien Vandersmissen	Received

353-P	FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL	Sabina Chiaretti	Received

355-P	MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRIAL	Fadi Haddad	Received

357-P	MULTICENTER RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOME OF ADULT PATIENS WITH MIXED-PHENOTYPE ACUTE LEUKEMIA (MPAL) DIAGNOSED AND TREATED IN THE LAST TEN YEARS. A CAMPUS-ALL STUDY.	Davide Lazzarotto	Received

359-P	IMPROVED OVERALL SURVIVAL AND MRD CLEARANCE WITH BLINATUMOMAB VS CHEMOTHERAPY AS PRE-TRANSPLANT CONSOLIDATION IN PEDIATRIC HIGH-RISK FIRST-RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)	Franco Locatelli	Received

361-P	EARLY MEASURABLE RESIDUAL DISEASE ANALYSIS IS ONLY PREDICTIVE OF SURVIVAL OUTCOMES AFTER TWO CYCLES OF TREATMENT IN ADULTS WITH B-LYMPHOBLASTIC LEUKEMIA RECEIVING HYPER-CVAD INDUCTION.	Rithin Nedumannil	Received

365-P	INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL)	Farhad Ravandi	Received

368-P	A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Jayastu Senapati	Received

369-P	A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Jayastu Senapati	Received

371-P	HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Nicholas Short	Received

372-P	DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB	Walid Macaron	Received

373-P	CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND METABOLIC FACTORS IN CHILDHOOD CANCER SURVIVORS	Emmanouil Athanasopoulos	Received

374-P	BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY	Irene Urbino	Received

377-P	GENETIC CHARACTERISTICS AND CD7-CAR-T THERAPY OF TRAD::MYC TRANSLOCATION POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Hongxing Liu	Received

380-P	EX VIVO IMMUNE ACTIVATION WITH THE MACROPHAGE-TARGETING IMMUNOTHERAPY, ANTI-CLEVER-1 ANTIBODY BEXMARILIMAB, IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME	Sofia Aakko	Received

383-P	USING CF-DNA AS STARTING MATERIAL FOR MRD STUDIES BY NGS IMPROVES THE SENSITIVITY OF THE METHOD AGAINST CTCS.	Noemí Álvarez Sánchez-Redondo	Received

385-P	DETECTION OF KMT2A PARTIAL TANDEM DUPLICATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS BY NGS	Alícia Artigas-Baleri	Received

387-P	UNRAVELING LEUKEMIC STEM CELLS MITOCHONDRIAL DEPENDENCY IN PEDIATRIC ACUTE MYELOID LEUKEMIA	Maddalena Benetton	Received

390-P	ACUTE MYELOID LEUKEMIA SUPPRESSION BY PALBOCICLIB AND PONATINIB IN PATIENT-DERIVED XENOGRAFT	Daniel Busa	Received

391-P	FLT3-ITD MEASUREMENT AT DIAGNOSIS AND FOR THE ASSESSMENT OF MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: CDNA VS. DNA	Diego Carbonell	Received

397-P	PROLACTIN RECEPTOR CONFERS CHEMORESISTANCE DUE TO SENESCENCE ENTRANCE IN ACUTE MYELOID LEUKEMIA	Laia Cuesta-Casanovas	Received

398-P	DEVELOPMENT AND CHARACTERIZATION OF PRECLINICAL IN VIVO MODELS FOR THE IDENTIFICATION AND TESTING OF NEW THERAPEUTIC APPROACHES FOR PEDIATRIC ACUTE MYELOID LEUKEMIA	Ambra Da Ros	Received

403-P	PROGNOSTIC SIGNIFICANCE OF LONG NON-CODING RNA GAS5 AND MICRORNA-222 EXPRESSION PROFILES IN YOUNGER AML PATIENTS	Ðorde Pavlovic	Received

409-P	NPM1 MUTATED SAMPLES ARE ESPECIALLY VULNERABLE WHEN TARGETING RAC1 IN PATIENT-DERIVED AML CELLS IN VITRO	Anette Hemsing	Received

415-P	TARGETED 3RD-GENERATION (NANOPORE) SEQUENCING REVEALS MANY NOVEL CIRCULAR RNAS OF THE APOPTOSIS-RELATED BCL2L12 GENE, EXPRESSED IN HUMAN CELLS FROM ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES	Christos Kontos	Received

416-P	CLONAL HEMATOPOIESIS IS COMMON IN AML LONG-TERM SURVIVORS AND MAY ASSOCIATE WITH DIABETES AND SECONDARY NEOPLASIAS, BUT NOT OTHER HEALTH OUTCOMES	Simon M. Krauß	Received

417-P	A SINGLE AMINO ACID AT THE PNT DOMAIN OF ERG MEDIATES ITS LEUKEMOGENIC ACTIVITY THROUGH INTERACTION WITH THE NCOR-HDAC3 CO-REPRESSOR COMPLEX.	Eitan Kugler	Received

420-P	FORCING LEUKAEMIC STEM CELL TO LEAVE QUIESCENT STATE BY INHIBITING HEDGEHOG, NOTCH AND WNT/BETA-CATENIN SIGNALLING PATHWAYS	Daniel Láinez-González	Received

425-P	ROLE OF LYSOSOMAL-ASSOCIATED GENE LAPMT4B IN LEUKEMIA	Jennifer Delgado-Martínez	Received

426-P	A SINGLE-CENTER RETROSPECTIVE ANALYISIS OF THE MUTATIONAL PROFILE IN ACUTE MYELOID LEUKEMIA PATIENTS	Yolanda Martínez Díez	Received

429-P	CLONALLY RESOLVED SINGLE-CELL MULTI-OMICS IDENTIFIES LEUKEMIA SURFACE ANTIGENS	Anne Kathrin Merbach	Received

430-P	MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB AZACITIDINE COMPARED TO PLACEBO AZACITIDINE	Steve Waye	Received

432-P	RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA: EXTERNAL VALIDATION OF THE STELLAE-123 GENE EXPRESSION MODEL AND COMPARISON WITH CURRENT PROGNOSTIC SCORES	Andres Peleteiro Raindo	Received

434-P	MITOCONDRIAL MCL1 REGULATES LEUKEMIC CELLS METABOLISM VIA DIRECT INTERACTION WITH HEXOKINASE II. METABOLIC SIGNATURE AT ONSET PREDICTS OVERALL SURVIVAL IN AMLS´ PATIENTS	Nelida Ines Noguera	Received

435-P	ANALYSIS OF MYELOBLAST IMMUNOPHENOTYPE PROFILE IN ACUTE MYELOID LEUKAEMIA AS PREDICTOR FOR CLINICAL OUTCOME	Mateusz Nowak	Received

436-P	TARGETED DELIVERY OF T22-PE24-H6 TO CXCR4 POSITIVE CELLS FOR ACUTE MYELOID LEUKEMIA TREATMENT	Yáiza Núñez Amela	Received

438-P	ARYL HYDROCARBON RECEPTOR SIGNALLING IN NORMAL HAEMATOPOIETIC (HSC) AND LEUKEMIA STEM CELLS (LSC): DIFFERENTIAL EFFECT OF AHR ANTAGONIST ON LSC COMPARED TO HSC	Alyona Oryshchuk	Received

439-P	ASSOCIATING EX VIVO DRUG SENSITIVITY WITH METABOLIC STATUS IDENTIFIES EFFECTIVE COMBINATION STRATEGIES IN ACUTE MYELOID LEUKEMIA	Diego A Pereira-Martins	Received

440-P	THE COMBINATION VENETOCLAX PLUS MCL1 OVERCOMES DRUG RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA	Diego A Pereira-Martins	Received

443-P	IMPACT OF PHARMACOGENETIC VARIANTS ON CYTARABINE AND ANTHRACYCLINE EFFECT ON OUTCOMES IN ADULT AML PATIENTS	Zlatko Pravdic	Received

444-P	IDENTIFICATION OF FUNCTIONAL GENETIC DEPENDENCIES IN CEBPA-MUTATED ACUTE MYELOID LEUKEMIA	Ludovica Proietti	Received

445-P	CRYPTIC TRANSLOCATION T(5;11)(Q35;P15) RESULTING IN NUP98::NSD1 GENE FUSION IN ADULTS WITH DE NOVO ACUTE MYELOID LEUKEMIA (AML)	Sarka Ransdorfova	Received

446-P	USE OF MIRNA EXPRESSION PATTERNS REVEALS ACTIVIN RECEPTOR 2 PATHWAY IN MEDIATING CHEMO-RESISTANT AML	Paula Reichelt	Received

447-P	BCL2-INHIBITION TARGETS LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF MONOCYTIC BLAST POPULATIONS	Simon Renders	Received

448-P	PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA	Frank G. Ruecker	Received

453-P	CDK6 DEGRADATION IS IMPEDED BY P16INK4A AND P18INK4C IN AML	Belinda Schmalzbauer	Received

454-P	VENETOCLAX AND GILTERITINIB SYNERGIZE IN FLT3 WILDTYPE ACUTE MYELOID LEUKEMIA BY SUPPRESSION OF MCL-1 VIA COMBINED AXL AND FLT3 TARGETING	Christina Schmidt	Received

455-P	BREAKING THE PUMP: TARGETING THE SODIUM-POTASSIUM PUMP AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA	Constanze Schneider	Received

460-P	RECOMBINANT SLIT2 INHIBITS ACUTE MYELOID LEUKEMIA CELL PROLIFERATION IN VITRO AND IN VIVO	Luise Araujo De Albuquerque Simoes	Received

461-P	MYELOID KINOME INHIBITOR HM43239 OVERCOMES ACQUIRED RESISTANCE IN ACUTE MYELOID LEUKEMIA MODELS	Rafael Bejar	Received

463-P	RE-PURPOSING OF GENE SIGNATURES IN AML UNCOVERS NOVEL ENERGETICS-ASSOCIATED MOLECULAR SUBTYPES	Paul Strain	Received

464-P	COMPARED TO CLASSICAL CYTOGENETICS OPTICAL GENOME MAPPING (OGM) DETECTS MULTIPLE ADDITIONAL STRUCTURAL CHROMOSOMAL ABERRATIONS IN PEDIATRIC ACUTE MYELOID LEUKEMIA (AML)	Julia Suttorp	Received

465-P	A LIPID NANOPARTICLE DELIVERY SYSTEM FOR TARGETING THE LEUKAEMIC FUSION GENE RUNX1/ETO BY SIRNA	Laura Swart	Received

467-P	FUNCTIONAL CHARACTERIZATION OF ABERRANT GATA1 PROTEIN COMPLEXES IN NORMAL AND MALIGNANT HUMAN ERYTHROBLASTS	Samantha Tauchmann	Received

468-P	MRD AS A BIOMARKER FOR RESPONSE TO DONOR LYMPHOCYTE INFUSION AFTER AL-LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Katrin Teich	Received

472-P	THE FLT3-ITD RECEPTOR CAN PROMOTE PROTEIN FOLDING IN THE ENDOPLASMIC RETICULUM THROUGH THE OXIDOREDUCTASE ERO1	Maria Turos Cabal	Received

473-P	DEVELOPMENT OF POTENTIAL BIOMARKERS FOR IRAK4 INHIBITOR EMAVUSERTIB IN HUMAN ACUTE MYELOID LEUKEMIA	Andrey Ugolkov	Received

474-P	PIEZO1 AND THE THERAPEUTIC POTENTIAL OF MECHANORECEPTORS IN ACUTE MYELOID LEUKAEMIA	Maria Velasco Estevez	Received

476-P	LOSS OF CHD4 IN ACUTE MYELOID LEUKAEMIA GIVES RISE TO INCREASED DNA DAMAGE REPAIR DEFECTS AND ALTERED CELL CYCLE PROGRESSION	Déirdra Venney	Received

478-P	THE GERMLINE VARIANT GFI1-36N PROMOTES GENETIC INSTABILITY IN LEUKEMIC CELLS AND OPENS NEW THERAPEUTIC APPROACHES FOR ABOUT 15% OF ALL AML PATIENTS	Jan Vorwerk	Received

479-P	DNA METHYLATION PROFILING REFINES THE PROGNOSTIC CLASSIFICATION OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH INTENSIVE CHEMOTHERAPY	Sebastian Vosberg	Received

480-P	NKG2D-MEDIATED ANTI-TUMOR IMMUNITY CONTRIBUTES TO THE FAVORABLE PROGNOSIS IN APL	Huaiyu Wang	Received

487-P	SMALL NON-CODING RNAS ASSOCIATE WITH CHROMATIN TO MAINTEIN PROPOGATION OF ACUTE MEYLOID LEUKEMIA	Haiyang Yun	Received

488-P	THZ1, A COVALENT CDK7 INHIBITOR, INDUCES APOPTOSIS IN ACUTE MYELOID LEUKEMIA CELLS AND EXERTS SYNERGISTIC ANTILEUKEMIA ACTIVITY WITH AZACITIDINE	Shuai Zhang	Received

491-P	PREDICTIVE FACTORS OF DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA	Mariem Ben Salah	Received

492-P	TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)	Eytan Stein	Received

504-P	CLINICAL MUTATIONAL ANALYSIS BY NEXT-GENERATION SEQUENCING AND REAL-LIFE VALIDATION OF THE REVISED 2017 EUROPEAN LEUKEMIANET GENETIC RISK STRATIFICATION IN AML PATIENTS	Clara Aparicio Pérez	Received

508-P	REAL LIFE EXPERIENCE USING FRONT-LINE CPX-351 FOR THERAPY-RELATED AND AML-MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY.	Teresa Bernal	Received

509-P	CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION	Lara Bischof	Received

518-P	PEDAL/EUPAL INTERNATIONAL COLLABORATION TO IMPROVE THE OUTCOME OF CHILDREN WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA	Valeria Ceolin	Received

528-P	A MIRNA SIGNATURE RELATED TO STEMNESS IDENTIFIES HIGH-RISK PATIENTS IN PEDIATRIC ACUTE MYELOID LEUKEMIA	Elena Esperanza Cebollada	Received

530-P	TAGRAXOFUSP IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM WITH/WITHOUT CENTRAL NERVOUS SYSTEM INVOLVEMENT AND INTRATHECAL CHEMOTHERAPY AS PRIMARY TREATMENT OR PROPHYLAXIS: AN ITALIAN EXPERIENCE.	Giulia Rivoli	Received

532-P	ACUTE MYELOID LEUKEMIA (AML): UNICENTRIC REPORT ON 1029 PATIENTS DIAGNOSED IN TERTIAL REFERAL CENTER	Anne Fricke	Received

534-P	AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS	Sylvain Garciaz	Received

535-P	UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).	Bruno Garibaldi	Received

536-P	VALUE OF MEASURABLE RESIDUAL DISEASE BY MULTIPARAMETRIC FLOW CYTOMETRY IN NON-PROMYELOCYTIC ACUTE MYELOID LEUKEMIA. REAL WORLD EVIDENCE	Alberto Daniel Gimenez Conca	Received

537-P	SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN ADULTS IN DENMARK FROM 2000 TO 2020: A POPULATION-BASED COHORT STUDY	Lars Klingen Gjærde	Received

539-P	PROGNOSTIC RELEVANCE OF MINIMAL RESIDUAL DISEASE IN THERAPY RELATED AND SECONDARY ACUTE MYELOID LEUKEMIA RECEIVING CPX-351 OR FLUDARABINE-BASED INDUCTION.	Fabio Guolo	Received

540-P	PEVONEDISTAT, AZACITIDINE AND VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA– A PHASE I STUDY	Guru Subramanian Guru Murthy	Received

545-P	CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND TRISOMY 19	Sabine Kayser	Received

546-P	EFFECTS OF CHEMOTHERAPY DOSE REDUCTIONS IN OVERWEIGHT AND OBESE PATIENTS WITH ACUTE MYELOID LEUKEMIA – A DANISH NATIONWIDE COHORT STUDY	Daniel Kristensen	Received

556-P	CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB AZACITIDINE OR PLACEBO AZACITIDINE	Steve Waye	Received

557-P	HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA	Hartmut Dohner	Received

558-P	GERMAN AMLCG-SURVIVORSHIP STUDY – SOMATIC LONG-TERM CONSEQUENCE OF AML AND ITS THERAPY: FROM HEART TO KIDNEY.	Anna Sophia Moret	Received

564-P	FINAL RESULTS OF THE QOLESS AZA-AMLE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY OF 5-AZA FOR POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS	Esther Natalie Oliva	Received

565-P	IMPROVED OUTCOME OF PATIENS WITH ACUTE MYELOID LEUKEMIA HARBORING FLT3 MUTATION IN THE ERA OF TARGETED THERAPY	Guadalupe Oñate	Received

566-P	IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)	Faustine Ong	Received

574-P	CPX-351 COMBINED WITH HEMATOPOIETIC CELL TRANSPLANTATION WITH REGULATORY AND CONVENTIONAL T CELL IMMUNOTHERAPY FOR HIGH-RISK ACUTE MYELOID LEUKEMIA	Sofia Sciabolacci	Received

578-P	GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS	Eitan Kugler	Received

585-P	VENETOCLAX IN COMBINATION WITH INTENSIVE TREATMENT PROTOCOLS FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA – A MULTICENTER REAL-WORLD ANALYSIS	Ofir Wolach	Received

587-P	COVALENT-101: A PHASE 1 STUDY OF BMF-219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, AND MULTIPLE MYELOMA	Farhad Ravandi-Kashani	Received

588-P	IMPROVED OUTCOME OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BY ADDITION OF LIPOSOMAL ADRIAMYCIN TO CLAG CHEMOTHERAPY	Han Yao	Received

589-P	AGE AND AGE-ADAPTED RISK FACTORS HIGHLY INFLUENCE SURVIVAL PROBABILITY IN AML PATIENTS – A RETROSPECTIVE ANALYSIS	Charlotte Zahner	Received

592-P	GILTERITINIB IN COMBINATION WITH VENETOCLAX, LOW DOSE CYTARABINE AND ACTINOMYCIN D FOR FLT3 MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA	Andrius Žucenka	Received

593-P	MULTIDIMENSIONAL ANALYSIS OF THE B CELL RECEPTOR OFFERS INSIGHT INTO THE ONTOGENETIC RELATIONSHIP OF MONOCLONAL B-CELL LYMPHOCYTOSIS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Andreas Agathangelidis	Received

595-P	DISCOVERY OF NOVEL CIRCULAR RNAS (CIRCRNAS) OF THE APOPTOSIS-RELATED BAX AND BCL2L12 GENES WITH A MULTIFACETED ROLE IN CHRONIC LYMPHOCYTIC LEUKEMIA, USING CUTTING-EDGE NANOPORE SEQUENCING TECHNOLOGY	Pinelopi Artemaki	Received

596-P	CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE	Riccardo Bomben	Received

599-P	RARE GERMLINE VARIANTS IN ATM INFLUENCE THE PATHOGENESIS OF CLL	Jennifer R. Brown	Received

600-P	HIGH-DEPTH RNA-SEQUENCING IDENTIFIES CD8+ STAT3 MUTATED T-LGLL PATIENTS AS A DISTINCT BIOLOGICAL ENTITY WITHIN THE DISEASE HETEROGENEITY	Giulia Calabretto	Received

604-P	CATALASE EXPRESSION IN LEUKEMIA CELLS IS CONTROLLED BY GENETIC AND EPIGENETIC MECHANISMS	Marilisa Galasso	Received

605-P	T-CELL PROLYMPHOCYTIC LEUKEMIA: MOLECULAR CHARACTERIZATION OF A COHORT OF 18 PATIENTS AND EVALUATION OF BORTEZOMIB AS A POSSIBLE THERAPEUTIC STRATEGY	Vanessa Rebecca Gasparini	Received

609-P	CLINICOBIOLOGICAL CHARACTERISTICS AND TREATMENT EFFICACY OF NOVEL AGENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH IGLV3-21R110	Paul Hengeveld	Received

612-P	CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)-DERIVED T-CELLS HAVE DISTURBED FATTY ACID METABOLISM, POSSIBLY CONTRIBUTING TO T-CELL DYSFUNCTION	Chaja F Jacobs	Received

622-P	DOUBLE-HIT TRAF3 DELETION AND MUTATION IDENTIFIED BY HIGH-THROUGHPUT SEQUENCING DEFINE A NEW INDEPENDENT PROGNOSTIC FACTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA	Claudia Perez-Carretero	Received

623-P	IBRUTINIB REGULATES MIR-181A/B VIA C-FOS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Alice Ramassone	Received

626-P	FUNCTIONAL SCREENING OF PI3K INHIBITORS STRATIFIES RESPONDERS TO IDELALISIB AND INDICATES DRUG CLASS ACTIVITY IN IDELALISIB-REFRACTORY CLL	Sigrid Skånland	Received

631-P	A PCR-BASED ASSAY FOR IGLV3-21R110 SCREENING CONFIRMS ITS PROGNOSTIC VALUE IN AN INDEPENDENT COHORT OF 613 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.	Charlotte Syrykh	Received

633-P	ACTIVE CHROMATIN REGULATORY LANDSCAPE OF STEREOTYPED SUBSETS IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS A DISTINCTIVE SIGNATURE IN SUBSET #8	Maria Tsagiopoulou	Received

634-P	MHC-BASED LARGE-SCALE SCREENING FOR ANTI-TUMOR T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS CD8+ T CELLS WITH SPECIFICITY AGAINST THE CLONOTYPIC B-CELL RECEPTOR IMMUNOGLOBULIN	Anna Vardi	Received

636-P	REAL WORLD OUTCOME WITH IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE GERMAN REALITY STUDY	Manfred Welslau	Received

637-P	FRONTLINE THERAPY CLL WITHOUT 17P DEL/P53 ABERRATIONS: SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS	Marco Rossi	Received

639-P	OUTCOMES FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH A COVALENT BTK AND BCL2 INHIBITOR IN THE UNITED STATES: A REAL-WORLD DATABASE STUDY	Anthony R. Mato	Received

640-P	PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY	Lindsey E. Roeker	Received

642-P	IMPACT OF TYPE 2 DIABETES ON SURVIVAL AND TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Emelie Curovic Rotbain	Received

644-P	THE LIFE EXPECTANCY OF PATIENTS WITH HAIRY CELL LEUKEMIA VERGES UPON THE LIFE EXPECTANCY OF THE GENERAL POPULATION: A POPULATION-BASED STUDY IN THE NETHERLANDS	Avinash Dinmohamed	Received

651-P	VENETOCLAX-BASED TREATMENT OF PATIENTS WITH RICHTER SYNDROME: OUTCOMES FROM A MULTICENTER RETROSPECTIVE STUDY	Paul Hampel	Received

652-P	MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUGH IGHV LEADER-BASED NEXT GENERATION SEQUENCING IMPROVES PROGNOSTIC STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA	Paul Hengeveld	Received

653-P	OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL-WORLD STUDY OF A LARGE U.S. DATABASE	Toby A Eyre	Received

656-P	INCIDENT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A POPULATION-BASED STUDY	Amber Koehler	Received

659-P	IBRUTINIB IN OVER-EIGHTIES PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER ITALIAN COHORT	Veronica Mattiello	Received

669-P	FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT	Carol Moreno	Received

670-P	ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V)	Lisa J. Croner	Received

671-P	TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS	Anthony R. Mato	Received

673-P	DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX.	Andy Rawstron	Received

674-P	UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Christine Ryan	Received

675-P	TREATMENT OF HYPERTENSION IN PATIENTS RECEIVING BTK INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY	Mazyar Shadman	Received

677-P	CLINICAL EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP	Anita Sobon	Received

680-P	SARCOPENIA EVALUATED BY CT SCAN IS ASSOCIATED WITH SHORTER SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH TARGETED THERAPIES. A PROSPECTIVE STUDY.	Andrea Visentin	Received

683-P	A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS)	Wojciech Jurczak	Received

684-P	PHASE 1 STUDY OF LP-108, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA	Wei Xu	Received

688-P	VIRTUAL SCREENING PROTOCOL TO IDENTIFY TYROSINE KINASE INHIBITORS WITH A POTENTIAL TO INTERACT WITH P-GLYCOPROTEIN AND TO ACT AS MDR CHEMOSENSITIZERS: A VALIDATION STUDY	Elina Beleva	Received

691-P	MODELLING OF IMMUNE RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS SUGGESTS POTENTIAL FOR TREATMENT REDUCTION PRIOR TO CESSATION	Ingmar Glauche	Received

694-P	INVESTIGATING THE ROLE OF CELL ADHESION MOLECULES IN TUNNELING NANOTUBES FORMATION IN CHRONIC MYELOID LEUKEMIA MICROENVIRONMENT	Laura Turos-Korgul	Received

696-P	SUBTHERAPEUTIC TKI DOSES FOR THE MAINTENANCE OF CML PATIENTS WITH INTOLERANCE OR REFUSAL TO DISCONTINUE: A SINGLE CENTER FEASIBILITY STUDY.	Asuncion Borrero	Received

697-P	PONATINIB IN A REAL-LIFE SETTING: A RETROSPECTIVE ANALYSIS FROM THE MONITORING REGISTRIES OF THE ITALIAN MEDICINES AGENCY (AIFA)	Massimo Breccia	Received

699-P	REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY	Timothy Devos	Received

707-P	DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS	Jane Apperley	Received

708-P	CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY.	Fatima Khadadah	Received

709-P	CLINICAL OUTCOME OF ASCIMINIB TREATMENT IN A REAL-WORLD MULTI-RESISTANT CML PATIENT POPULATION.	Camille C.B. Kockerols	Received

711-P	KINETICS OF CITED2 GENE EXPRESSION IN CHRONIC MYELOID LEUKEMIA PATIENTS	Basma Atef	Received

716-P	OUTCOMES AND PATTERNS OF TREATMENT IN CHRONIC MYELOID LEUKEMIA, A GLOBAL PERSPECTIVE BASED ON A REAL-WORLD DATA GLOBAL NETWORK	Alejandro Sanz	Received

717-P	BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL	Jorge E Cortes	Received

721-P	PREDICTIVE SCORING SYSTEMS FOR MOLECULAR RESPONSES IN PERSONS WITH CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL IMATINIB THERAPY	Xiaoshuai Zhang	Received

723-P	LOSS OF THE NK MOTIF AND ANKYRIN REPEAT DOMAIN 1 (KANK1) LEADS TO LYMPHOID COMPARTMENT DYSREGUATION IN MICE	Marwa Almosailleakh	Received

724-P	THE BONE MARROW MESENCHYMAL CELL-DERIVED EXTRACELLULAR MATRIX IS SIGNIFICANTLY ALTERED IN PATIENTS WITH MELODYSPLASTIC SYNDROMES	Amanpreet Bains	Received

725-P	METABOLIC PROPERTIES OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES	Manja Wobus	Received

726-P	MYELOID-DERIVED SUPPRESSOR CELLS AS POTENTIAL TARGETS FOR IMMUNE THERAPY IN CCUS AND LOW RISK MDS	Sofia Bentivegna	Received

728-P	GENE EXPRESSION PROFILE REVELS T-LYMPHOCYTES ACTIVATION THROUGH CELL CYCLE PROGRESSION AND MITOCHONDRIAL METABOLISM REGULATION IN MYELODYSPLASTIC SYNDROMES WITH DEL(5Q) AFTER LENALIDOMIDE TREATMENT	Mónica Del Rey	Received

729-P	DEREGULATION OF NONCODING RNAS DERIVED FROM KDM GENES IS ASSOCIATED WITH AZACITIDINE RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA	Michaela Dostalova Merkerova	Received

731-P	INTERPLAY BETWEEN INFLAMMATION AND EPIGENETICS IN TUMOR REPROGRAMMING OF MESENCHYMAL STROMAL CELLS (MSCS) IN MYELODYSPLASTIC SYNDROMES (MDS)	Cesarina Giallongo	Received

732-P	TH17/TREG IMBALANCE IN LOW RISK MDS PATIENTS	Sofia Grille	Received

733-P	DHX9 HELICASE DYSFUNCTION CONTRIBUTES TO DISEASE PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Feng Xu	Received

734-P	DOWN-REGULATION OF RING1 AND YY1 BINDING (RYBP) LEADS TO EPIGENETIC OVEREXPRESSION OF ANTI-APOPTOTIC PROTEIN BCL2 IN MYELODYSPLASTIC SYNDROMES	Feng Xu	Received

736-P	BCOR MUTATION REGULATES MYELODYSPLASTIC SYNDROMES PROGRESSION THROUGH REPRESSING AUTOPHAGY FLUX MEDIATED BY HDAC6 ACTIVATION	Wu Lingyun	Received

739-P	THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML	Anair Graciela Lema Fernandez	Received

742-P	TRANSCRIPTOMIC ANALYSIS OF ISOLATED CD4+ AND CD8+ T CELLS REVEALS DIFFERENCES IN TCR REPERTOIRE IN PATIENTS WITH HIGH RISK MDS COMPARED TO AML.	Ioannis Mitroulis	Received

751-P	CHARACTERIZING CIRCULAR RNA EXPRESSION IN MYELODYSPLASTIC SYNDROME	Eileen Wedge	Received

752-P	TARGETING S100A9 IN THE MYELODYSPLASTIC INFLAMMATORY BONE MARROW MICROENVIRONMENT BY TASQUINIMOD IMPROVES THE SUPPORTIVE FUNCTION OF MESENCHYMAL STROMAL CELLS	Manja Wobus	Received

755-P	HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML	Luis E. Aguirre	Received

758-P	INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY	Andrew Brunner	Received

761-P	MONOCYTOSIS IN PRIMARY CARE AND HEMATOLOGICAL MALIGNANCIES	Mathilde Christensen	Received

762-P	NONLINIEAR IMPACT OF CLINICAL FEATURES ON THE SURVIVAL OUTCOME OF MYELODYSPLASTIC SYNDROMES PATIENTS	Faezeh Darbaniyan	Received

764-P	RESPONSE AND SURVIVAL OUTCOMES WITH HYPOMETHYLATING AGENTS IN AN ARGENTINEAN COHORT OF 113 PATIENTS WITH CHRONIC MYELOMONOCITIC LEUKEMIA	Jacqueline Gonzalez	Received

766-P	CLINICAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED ANALYSIS	Amer M. Zeidan	Received

771-P	PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY	Joana Kostova	Received

772-P	PROGNOSTIC IMPACT OF DISEASE-RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)	Claudia Lesch	Received

777-P	RUNX1 VARIANTS WITH HIGH VARIANT ALLELE FREQUENCY IN MYELOID NEOPLASMS. GERMLINE OR NOT?	Nikolaj Juul Nitschke	Received

787-P	SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM	Amer M. Zeidan	Received

792-P	CRISPR/CAS9-BASED MODEL OF HETEROZYGOUS CXCR4 WT/R334X MUTATION TO STUDY CELLULAR PHENOTYPES IN WHIM SYNDROME	Katarina Zmajkovicova	Received

793-P	SCREENING OF NATURALLY OCCURRING CXCR4 VARIANTS FOR IDENTIFICATION OF NOVEL PATHOGENIC MUTATIONS FOR WHIM SYNDROME	Sumit Pawar	Received

797-P	METABOLIC PROFILING IN ERCC6L2 AND SHWACHMAN DIAMOND SYNDROME	Ilse Kaaja	Received

803-P	TELOMERE SHORTENING IN BONE MARROW MESENCHYMAL STEM CELLS OF ACQUIRED APLASTIC ANEMIA PATIENTS ASSOCIATE WITH ALTERED EXPRESSION OF GENES INVOLVED IN TELOMERE MAINTENANCE, DNA DAMAGE, AND SENESCENCE	Jyotika Srivastava	Received

806-P	IMPACT OF MARROW HEMOPHAGOCYTOSIS IN DIAGNOSTIC DEFINITION AND PROGNOSTIC SIGNIFICANCE IN ADULT POPULATION	Cátia Almeida	Received

808-P	CONGENITAL NEUTROPENIA PREVALENCE AMONG POLISH CHILDREN – SUMMARY OF A NATIONWIDE GENETIC SCREENING CAMPAIGN	Katarzyna Babol-Pokora	Received

817-P	SYNDROMES PREDISPOSING TO LEUKEMIA ARE A MAJOR CAUSE OF INHERITED CYTOPENIAS IN CHILDREN	Oded Gilad	Received

819-P	TRANSPLANT, TREATMENT AND TRANSFUSION FREE (TTT-FREE) SURVIVAL AS RELEVANT CLINICAL ENDPOINT AFTER IMMUNOSUPPRESSIVE TREATMENT FOR ACQUIRED APLASTIC ANEMIA IN ADULTS	Cjm Halkes	Received

825-P	FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAVE TO C5 INHIBITORS	Jordan Messer	Received

826-P	FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS	Jordan Messer	Received

832-P	CLINICAL OUTCOMES AND IMMUNE RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA	Roma Rajput	Received

835-P	GENETIC BACKGROUND AND CLINICAL CHARACTERISTICS OF CONGENITAL NEUTROPENIAS IN ISRAEL	Orna Steinberg-Shemer	Received

841-P	EXTRACELLULAR VESICLE PROTEINS AS BIOMARKER OF OUTCOME IN MULTIPLE MYELOMA - A REAL-WORLD STUDY	Emilie Arnault Carneiro	Received

842-P	NOVEL MULTIFUNCTIONAL TETRAVALENT CD38 NKP46 FLEX-NK ENGAGERS ACTIVELY TARGET AND KILL MULTIPLE MYELOMA CELLS	Antonio Arulanandam	Received

845-P	IDENTIFICATION OF MULTIPLE MYELOMA BIOMARKERS VIA LIQUID BIOPSY BASED ON CELL-FREE DNA USING A CAPTURE-HYBRIDIZATION PANEL	Natalia Buenache Cuenda	Received

846-P	EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME.	Cristina De Ramón	Received

848-P	TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA	Andrea Diaz-Tejedor	Received

849-P	DEPLETION OF DIS3 IN MULTIPLE MYELOMA LEADS TO PERTURBATION IN RNA METABOLISM, CELL CYCLE PROGRESSION AND MITOTIC CHECKPOINT.	Vanessa Favasuli	Received

851-P	TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA	Lama Hasan Bou Issa	Received

855-P	SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA	Ulrich Keller	Received

857-P	BORTEZOMIB- AND CARFILZOMIB-RESISTANT MYELOMA CELLS SHOW INCREASED ACTIVITY OF ALL THREE ARMS OF UNFOLDED PROTEIN RESPONSE AND ENRICHMENT OF SIRTUIN SIGNALING PATHWAY	Tadeusz Kubicki	Received

858-P	EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR T-CELL CYTOTOXICITY	Laura Martinez-Verbo	Received

859-P	ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS	Elena Meseguer Martinez	Received

861-P	SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY	Alessandro Natoni	Received

863-P	GENERATION OF A FIRST-IN-CLASS INHIBITOR FOR THE MASTER ONCOREGULATOR HNRNP K IN MULTIPLE MYELOMA	Álvaro Otero Sobrino	Received

864-P	CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA - SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION	Christina Pfeiffer	Received

869-P	PRODUCTION BY GUT MICROBIOTA AS PROGNOSTIC BIOMARKER IN MM	Alba Rodríguez-García	Received

872-P	DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE	Anaïs Schavgoulidze	Received

873-P	CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS	Anja Schneller	Received

875-P	ACTIVATION OF LNCRNA NEAT1 LEADS TO SURVIVAL ADVANTAGE OF MULTIPLE MYELOMA CELLS BY SUPPORTING A REGULATORY LOOP WITH DNA REPAIR PROTEINS: RATIONAL BASES FOR NEAT1 THERAPEUTIC TARGETING IN THE DISEASE	Elisa Taiana	Received

879-P	EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA	Stefanie Huhn	Received

888-P	REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY	Frida Bugge Askeland	Received

889-P	WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)	Frida Bugge Askeland	Received

891-P	IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01	Xavier Leleu	Received

894-P	A PHASE II TRIAL TO EVALUATE THE EFFICACY OF DARATUMUMAB WITH DCEP IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER BORTEZOMIB BASED TREATMENT	Ja Min Byun	Received

897-P	UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA	Andrew Dalovisio	Received

900-P	SALVAGE AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED MULTIPLE MYELOMA: A SINGLE CENTRE EXPERIENCE	Sara Duarte	Received

902-P	RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY	Francesca Fazio	Received

905-P	IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13	Kaz Groen	Received

906-P	IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY	Kaz Groen	Received

907-P	CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY	Hang Quach	Received

911-P	SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE AMONG PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) – FINDINGS FROM AN INTERNATIONAL IMCD PATIENT SURVEY	Sudipto Mukherjee	Received

916-P	COEXISTENCE OF =2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE GREEK MYELOMA STUDY GROUP	Eirini Katodritou	Received

917-P	HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK	Felix Keil	Received

918-P	HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS	Jahanzaib Khwaja	Received

923-P	TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATIONS STILL BENEFIT FOR MYELOMA PATIENTS: A POOLING META-ANALYSIS	Cho-Hao Lee	Received

926-P	DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL	Lisa Leypoldt	Received

928-P	REAL-LIFE ANALYSIS OF THE MULTIPLE MYELOMA PATIENT´S SURVIVAL IN A LARGE COHORT OF PATIENTS	Nieves Lopez-Muñoz	Received

929-P	IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).	Margaret Macro	Received

931-P	PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE	Gaetano Giuffrida	Received

932-P	ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY	Roberto Mina	Received

933-P	DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY	Andrew Spencer	Received

934-P	DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN	Cesar Rodriguez	Received

936-P	TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY	Thierry Facon	Received

938-P	CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE CONSOLIDATION IN MYELOMA PATIENTS WITH A POSITIVE FDG PET/CT AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION: A PHASE II STUDY (CONPET)	Jakob Nordberg Nørgaard	Received

944-P	A PHASE I STUDY OF C-CAR088, A NOVEL HUMANIZED ANTI-BCMA CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Xiaoyan Qu	Received

945-P	SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS	Hang Quach	Received

948-P	INCIDENCE AND CLINICAL OUTCOME OF SARS-COV-2 INFECTION AFTER VACCINATION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS)	Nicola Sgherza	Received

950-P	COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE	Tobias S. Slørdahl	Received

952-P	THE ROLE OF AGE IN THE LONG-TERM TREATMENT OF MULTIPLE MYELOMA - A LONGITUDINAL ANALYSIS OF REGULAR CARE DATA	H Tilman Steinmetz	Received

963-P	EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT	David Kuter	Received

966-P	DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE	Iuliana Vaxman	Received

968-P	ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202	Peter Voorhees	Received

970-P	SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA	Ying Gao	Received

973-P	REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY	Katja Weisel	Received

979-P	EXOSOMES IN POLYCYTHEMIA VERA: "MINI PLATELETS" WITH THROMBOGENIC POTENTIAL	Adi Abulafia	Received

980-P	JAK2V617F-DEPENDENT DOWN REGULATION OF SHP1 EXPRESSION PARTICIPATES IN THE SELECTION OF MPN CELLS IN THE PRESENCE OF TGF?	Celine Aoun	Received

982-P	MYELOID-DERIVED SUPPRESSOR CELLS: CHARACTERIZATION IN PERIPHERAL BLOOD AND SPLEEN TISSUE OF PATIENTS WITH MYELOFIBROSIS	Rita Campanelli	Received

983-P	SINGLE CELL ANALYSIS ALLOWS THE EARLY DETECTION OF LEUKEMIC CLONES IN MPN PATIENTS	Chiara Carretta	Received

984-P	MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)	Ilaria Carola Casetti	Received

985-P	THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF	Giacomo Coltro	Received

986-P	CYTOGENETIC DIAGNOSIS WITH NEXT-GENERATION CYTOGENETICS BY OPTICAL GENOME MAPPING IN PATIENTS WITH MYELOFIBROSIS.	Álvaro Díaz González	Received

987-P	A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME	Elena Genovese	Received

988-P	LACTATE RESHAPES TUMOR MICROENVIRONMENT AND METABOLIC PROFILE IN MYELOFIBROSIS	Sebastiano Giallongo	Received

990-P	T CELL RESPONSE AND OMICRON VARIANT NEUTRALISATION FOLLOWING VACCINATION AGAINST SARS-COV-2 IN PATIENTS WITH CHRONIC MYELOID DISORDERS	Patrick Harrington	Received

991-P	IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB	Patrick Harrington	Received

992-P	OUTCOMES OF GLOBAL COAGULATION ASSAYS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH RESPECT TO THEIR CLINICAL AND GENETIC DETERMINANTS OF CLONAL EVOLUTION	Alessandro Lucchesi	Received

993-P	SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS	Manuela Mancini	Received

995-P	MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT	Barbara Mora	Received

1002-P	ANTI-FIBROTIC ACTIVITY OF BMP2 IN BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS OF MYELOPROLIFERATIVE NEOPLASMS	Tijana Suboticki	Received

1003-P	PERIPHERAL BLOOD CYTOTOXIC T CELLS SHOW EARLY EXHAUSTED FEATURES IN MYELOFIBROSIS PATIENTS	Lara Tavernari	Received

1005-P	A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS	Haris Ali	Received

1010-P	RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME	Francesca Palandri	Received

1011-P	PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB	Francesca Palandri	Received

1016-P	POLYCYTHEMIA VERA AND IMMUNE THROMBOGENESIS	Rossella Cacciola	Received

1021-P	ERYTHROCYTOSIS, THROMBOCYTOSIS AND RATE OF RECURRENT THROMBOEMBOLIC EVENT - A POPULATION BASED COHORT STUDY	Anneli Enblom-Larsson	Received

1025-P	RUXOLITINIB-ASSOCIATED CRYPTOCOCCOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS	Mihnea-Alexandru Gaman	Received

1028-P	PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA	Andrew Kuykendall	Received

1032-P	REAL-LIFE VALIDATION OF MIPSS70: A RETROSPECTIVE MULTICENTER AND NGS ANALYSIS FROM THE GEMFIN DATABASE	Alberto Hernández-Sánchez	Received

1033-P	A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)	Alycia Shilton	Received

1037-P	DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES	Claire Harrison	Received

1043-P	OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER	Lucia Masarova	Received

1045-P	IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?	Erika Morsia	Received

1046-P	SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS	Wolfgang Novak	Received

1048-P	MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR	Faye Feller	Received

1051-P	A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS	Alycia Shilton	Received

1052-P	IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS	Jayastu Senapati	Received

1055-P	CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA	Frank Stegelmann	Received

1057-P	REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE	Claire Harrison	Received

1060-P	REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE	John Mascarenhas	Received

1062-P	A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY	Aaron T. Gerds	Received

1063-P	EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY	Abdulraheem Yacoub	Received

1064-P	CIRCULATING CYTOKINE LEVELS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS – PROFILE AND CLINICAL CORRELATIONS – A SINGLE CENTER STUDY	Gergana Tsvetkova	Received

1065-P	CONGENITAL ERYTHROCYTOSIS DUE TO HETEROZYGOUS VARIANTS IN THE BISPHOSPHOGLYCERATE MUTASE GENE	Myrthe J. Van Dijk	Received

1067-P	PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS	Ji-Nuo Wang	Received

1074-P	PRIMARY REFRACTORY HODGKIN´S LYMPHOMA: A MOROCCAN MONOCENTRIC RETROSPECTIVE STUDY	Mounir Ababou	Received

1075-P	EVALUATION OF CYTOKIN GENE POLYMOPHISMS AND GENE EXPRESSIONS IN PATIENTS WITH HODGKIN LYMPHOMA	Handan Haydaroglu Sahin	Received

1076-P	A RETROSPECTIVE ANALYSIS ON OLD AND EMERGING PROGNOSTIC FACTORS IN CLASSICAL HODGKIN´S LYMPHOMA IN THE PET-GUIDED ERA	Alessandro Cellini	Received

1078-P	PATIENTS WITH HODGKIN LYMPHOMA DEVELOP ADEQUATE HUMORAL SEROLOGICAL RESPONSE TO VACCINATION WITH TWO DOSES OF BNT162B2 AND THEIR IGG ANTIBODY LEVELS MARKEDLY INCREASE AFTER A THIRD VACCINE DOSE	Eldad Dann	Received

1079-P	COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA	Daniel Ermann	Received

1081-P	PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL	Astrid Pavlovsky	Received

1082-P	SAFETY AND EFFICACY ANALYSIS IN OLDER PATIENTS TREATED WITHIN THE GATLA LH-05 PROTOCOL: PET-ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA	Nancy Lorena Fiad	Received

1083-P	BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY	Ramon Garcia-Sanz	Received

1084-P	CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN´S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP).	Francesco Gaudio	Received

1085-P	EVALUATION OF GONADAL FUNCTION IN YOUNG WOMEN DIAGNOSED WITH HODGKIN AND NON-HODGKIN LYMPHOMA	Angeliki N. Georgopoulou	Received

1092-P	NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA (NLPHL): HISTOLOGYCAL AND CLINICAL REVIEW IN A SINGLE CENTRE.	Elena Rámila	Received

1093-P	A NEW PROGNOSTIC MODEL FOR INDIVIDUAL OUTCOME PREDICTION IN ADVANCED-STAGE HODGKIN LYMPHOMA.	Rasmus Rask Kragh Jørgensen	Received

1094-P	CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER	Hadiyah Audil	Received

1095-P	TREATMENT ATTRIBUTES FOR 3RD LINE FOLLICULAR LYMPHOMA TREATMENT DECISION-MAKING: PHYSICIAN PERSPECTIVES FROM A SURVEY ACROSS WESTERN EUROPE AND THE UNITED STATES	P. Connor Johnson	Received

1096-P	TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA	Allison Bock	Received

1098-P	OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN MAINTENANCE TREATMENT WITH ANTICD20 MONOCLONAL ANTIBODIES IN SARS-COV2 ERA: RESULTS FROM A MULTICENTER, RETROSPECTIVE- PROSPECTIVE ITALIAN STUDY.	Alessia Castellino	Received

1100-P	BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)	Martin Dreyling	Received

1101-P	PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY	Toby A. Eyre	Received

1105-P	FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM´S MACROGLOBULINEMIA	Meletios-Athanasios Dimopoulos	Received

1106-P	PRELIMINARY RESULTS OF A PHASE 1 STUDY OF NOVEL BCL-2 INHIBITOR LISAFTOCLAX (APG-2575) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMAS (NHLS)	Mingyuan Sun	Received

1107-P	CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY	Ulrich Jaeger	Received

1108-P	HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA	Shalev Fried	Received

1110-P	EFFICACY AND SAFETY OF IMMUNOCHEMOTHERAPY IN TREATMENT OF FOLLICULAR NON-HODGKIN´S LYMPHOMA DURING COVID-19 PANDEMIC: A STUDY OF KROHEM, THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES	Barbara Dreta	Received

1112-P	TREATING BING-NEEL SYNDROME USING A TAILORED APPROACH: EXPERIENCE OF A SPECIALIST NEUROHAEMATOLOGY CLINIC	Jahanzaib Khwaja	Received

1114-P	ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY	Jacob D. Soumerai	Received

1120-P	THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA	Wenming Chen	Received

1122-P	EFFICACY OF ALPELISIB IN PI3K-DRIVEN LANGERHANS CELL HISTIOCYTOSIS	Roei Mazor	Received

1123-P	TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)	Vladimir Vorobyev	Received

1128-P	CLINICAL FEATURES AND OUTCOME OF PATIENTS WITH CASTLEMAN DISEASE: A SPANISH MULTICENTRIC STUDY OF 134 PATIENTS FROM GELTAMO	Jose Tomas Navarro	Received

1132-P	PET INTERIM RESULTS PREDICT PROGRESSION-FREE-SURVIVAL IN FOLLICULAR LYMPHOMA PATIENTS WITH ADVANCED STAGE	Maria Poza	Received

1133-P	SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.	Guillaume Cartron, Md, Phd	Received

1134-P	OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA POST-CBTK INHIBITOR THERAPY IN THE UNITED STATES AND JAPAN: A STUDY OF TWO REAL-WORLD DATABASES	Shinya Rai	Received

1136-P	INTERIM IMAGING DOES NOT PREDICT CLINICAL EVOLUTION IN FOLLICULAR LYMPHOMA IN A REAL-LIFE CLINICAL SETTING	Victoria Ramos De Ascanio	Received

1138-P	COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL	Pier Luigi Zinzani	Received

1140-P	TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE	Frits Van Rhee	Received

1141-P	IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY	Ann Tivey	Received

1149-P	THE EVOLVING STATE OF PLAY IN 1000 PATIENTS WITH WALDENSTRÖM´S MACROGLOBULINAEMIA IN THE UNITED KINGDOM (UK): A REAL-WORLD DATA ANALYSIS FROM THE WMUK RORY MORRISON REGISTRY PROJECT	Encarl Uppal	Received

1150-P	REAL WORLD DATA ON BORTEZOMIB-BASED THERAPY IN WALDENSTRÖM´S MACROGLOBULINAEMIA: EFFECTIVE EVEN IN MULTIPLY TREATED PATIENTS INCLUDING PRIOR BTK-INHIBITORS	Encarl Uppal	Received

1151-P	METABOLIC TUMOR VOLUME IMPROVES OUTCOME PREDICTION IN UNTREATED MANTLE CELL LYMPHOMA	Vibeke Kj Vergote	Received

1152-P	RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)	Ann Maclaren	Received

1154-P	STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA	Salim Yazji	Received

1155-P	BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM	Yucai Wang	Received

1157-P	REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA	Bijal Shah	Received

1158-P	REAL-WORLD TREATMENT PATTERNS AND ECONOMIC BURDEN OF PATIENTS WITH MARGINAL ZONE LYMPHOMA	Bijal Shah	Received

1160-P	RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA	Jorge J. Castillo	Received

1168-P	CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS	Allison Bock	Received

1169-P	ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES	Stephen Boyle	Received

1170-P	INCIDENCE, TREATMENT AND OUTCOME OF PATIENTS WITH RICHTER´S SYNDROME: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS	Mirian Brink	Received

1172-P	DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS	Pier Luigi Zinzani, Md, Phd	Received

1176-P	RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY	Jeanette Doorduijn	Received

1177-P	PROGNOSTIC VALUE OF TP53 VARIANTS IN CHILDREN WITH MATURE B-CELL LYMPHOMA TREATED ACCORDING TO REDUCED-INTENSITY B-NHL-2010M PROTOCOL	Volchkov Egor	Received

1180-P	ARE EXTRANODAL LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA MORE AGRESSIVE THAN NODAL FORMS?	Catarina Fernandes	Received

1183-P	CAR-T MORPHOLOGICAL CHARACTERISTICS AND DYNAMICS IN PERIPHERAL BLOOD, EVALUATED BY A NOVEL MICROSCOPY PLATFORM	Gil Fridberg	Received

1185-P	ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.	C. Li	Received

1187-P	END OF TREATMENT 18F FDG-PET/CT RESPONSE IS PROGNOSTIC FOR OVERALL AND PROGRESSION-FREE SURVIVAL IN PERIPHERAL T-CELL LYMPHOMA: RESULTS OF THE UK NCRI PHASE 2 RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY	Mary Gleeson	Received

1194-P	A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)	Tapan Kadia	Received

1195-P	A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.	Matko Kalac	Received

1199-P	MACHINE-LEARNING ALGORITHM TO DETECTION OF LYMPHOMA WITH BONE MARROW INVOLVEMENT VIA FDG-18 PET/CT	Cho-Hao Lee	Received

1201-P	ZANUBRUTINIB PLUS RCHOP(ZR-CHOP) REGIMEN ACHIEVES HIGH COMPLETE RESPONSE RATE IN THE TREATMENT OF NEWLY-DIAGNOSED DOUBLE-EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA	Zengjun Li	Received

1207-P	MULTICENTER RANDOMIZED CONTROLLED (COMPARATIVE) OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF THE R-DA-EPOCH-21 AND R-MNHL-BFM-90 ± AUTO- HSCT PROGRAMS IN PATIENTS WITH DE NOVO DIFFUSE B-CELL LAR	Aminat Magomedova	Received

1209-P	INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS	Frederik O. Meeuwes	Received

1220-P	CHARACTERISTICS OF SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA – A SUPPLEMENTARY ANALYSIS OF JCOG0601	Kazuyuki Shimada	Received

1223-P	PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN(ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)	Youhong Tang	Received

1224-P	EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS	Amal Haujir	Received

1225-P	SECONDARY PRIMARY MALIGNANCIES (SPM) AFTER HIGH-DOSE CHEMOTHERAPY (HDT) WITH AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR LYMPHOMA: A DANISH NATIONWIDE COHORT STUDY	Trine Trab	Received

1227-P	POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY	Bahar Uncu Ulu	Received

1240-P	ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL	Lei Zhang	Received

1246-P	DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA	Pilar Andersen	Received

1250-P	EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA	Fiona Brown	Received

1251-P	BONE-BASED 3D SCAFFOLD AS AN IN-VITRO MODEL OF MICROENVIRONMENT-LYMPHOMA INTERACTION	Jessica Ceccato	Received

1253-P	MAVORIXAFOR DISRUPTS THE CROSS TALK BETWEEN WALDENSTRMS MACROGLOBULINEMIA CELLS AND THE BONE MARROW MICROENVIRONMENT RESULTING IN ENHANCED SENSITIVITY TO B-CELL TARGETED THERAPIES	Halenya Monticelli	Received

1254-P	RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS	Vera De Jonge	Received

1255-P	TUMOR-ASSOCIATED MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS IS A POTENTIAL PROGNOSTIC BIOMARKER, PROMOTING MULTI-DRUG RESISTANCE IN NHL PATIENTS BY MODULATING IL-6/IL-10/IL-1? AXIS	Sukanya Dhar	Received

1256-P	A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY	Daniela Drandi	Received

1259-P	CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA	Agnete Granau	Received

1260-P	UNRAVELING THE GENETICS OF TRANSFORMED SPLENIC MARGINAL ZONE LYMPHOMA	Marta Grau	Received

1262-P	EZH2 INHIBITORS MEDIATE PLATINUM RESISTANCE BY ENHANCED EFFLUX	Elisabeth Groß	Received

1263-P	A SENSITIVE NGS ASSAY TO DETECT MEASURABLE RESIDUAL DISEASE (MRD) IN B-CELL LYMPHOPROLIFERATIVE DISEASES	Presha Shah	Received

1264-P	HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY	Simon Husby	Received

1267-P	HSP110 FAVORS BCR SIGNALING THROUGH SYK PHOSPHORYLATION IN DIFFUSE LARGE B CELL LYMPHOMA	Vincent Cabaud Gibouin	Received

1268-P	DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).	Yanrong Jiang	Received

1270-P	IMMUNE REGULATORY CELLS IN B-CELL LYMPHOMAS: SIGNIFICANT HETEROGENEITY ACROSS HISTOLOGIC TYPES.	Christina Kalpadakis	Received

1273-P	INVESTIGATING THE ONCOGENIC POTENTIAL OF STAT5BN642H IN NK CELLS	Klara Klein	Received

1274-P	EARLY DETECTION OF NON-HODGKIN LYMPHOMA IN PREDISPOSED PATIENT GROUPS THROUGH IMMUNOGENETIC SEQUENCING	Pieter Martijn Kolijn	Received

1275-P	PERCENTAGE OF TUMOR INFILTRATING T LYMPHOCYTES MEASURED BY FLOW CYTOMETRY AT DIAGNOSIS PREDICTS SURVIVAL AFTER SALVAGE CHEMOTHERAPY IN RELAPSED/ REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PATIENTS.	Laura Korin	Received

1277-P	MUTATIONAL LANDSCAPE AND COPY NUMBER ALTERATIONS IN TESTICULAR LARGE B-CELL LYMPHOMA	Cristina López	Received

1278-P	ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-CELL LYMPHOMA (TCL).	John Sanil Manavalan, Md	Received

1279-P	INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH	Sabrina Manni	Received

1282-P	DISEASE-SPECIFIC U1 SPLICEOSOMAL RNA MUTATIONS IN MATURE B-CELL NEOPLASMS	Ferran Nadeu	Received

1284-P	LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS	Ana Jiménez-Ubieto	Received

1287-P	DISTINGUISHING BETWEEN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING THE LYMPH3CX GENE EXPRESSION PROFILING ASSAY	Ryan S. Robetorye	Received

1289-P	COMPUTATIONAL SIMULATIONS SHED LIGHT ON THE 3D CONSEQUENCE OF SUPER-ENHANCER HIJACKING IN B CELL MALIGNANCIES	Lisa Russell	Received

1292-P	MOLECULAR CHARACTERIZATION OF DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED TO HEPATITIS C VIRUS INFECTION	Roberta Sciarra	Received

1295-P	DECIPHERING THE ROLE OF MSI2 AS A REGULATOR OF MANTLE CELL LYMPHOMA STEM-LIKE PROPERTIES	Marta Sureda-Gómez	Received

1297-P	ABERRANT MYCN EXPRESSION DRIVES ONCOGENIC HIJACKING OF EZH2 AS A TRANSCRIPTIONAL ACTIVATOR IN PERIPHERAL T CELL LYMPHOMA	Marlies Vanden Bempt	Received

1299-P	LOSS OF TYROSINE PHOSPHATASE SHP1 SENSITIZES DLBCL TO IBRUTINIB: A CANDIDATE PREDICTIVE BIOMARKER	Y. Lynn Wang	Received

1303-P	POTENTIATING ANTI-CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS	Adrian Wiestner	Received

1304-P	THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL)	Ioanna Xagoraris	Received

1305-P	HSA_CIRC_0001599 REGULATES IL18 LEVELS IN AGVHD VIA CERNA MECHANISM	Mengting Xia	Received

1307-P	TESTING THE IMPORTANCE OF ANTIOXIDANTS ON THE PATHOGENESIS OF B CELL LYMPHOMA	Haidong Yao	Received

1310-P	A ROBUST APPROACH FOR THE GENERATION OF FUNCTIONAL HEMATOPOIETIC PROGENITOR CELL LINES TO MODEL LEUKEMIC TRANSFORMATION	Eszter Doma	Received

1313-P	PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH	Madlen Jentzsch	Received

1316-P	ASSESSING GENOMIC SAFETY OF ANTIVIRAL NUCLEOSIDE ANALOGS IN HEMATOPOIETIC STEM CELLS	Flavia Peci	Received

1317-P	TIME SERIES CLUSTERING OF T CELL SUBSETS DISSECTS HETEROGENEITY IN IMMUNE RECONSTITUTION AND SURVIVAL AMONG RECIPIENTS OF MUD-HCT WITH ATG OR PTCY	Amin Turki	Received

1319-P	T AND B LYMPHOCYTES SUBSETS AFTER BNT162B2 ANTI-SARS-COV-2 M-RNA VACCINATION: A COMPARISON BETWEEN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS AND HEALTHY CONTROLS.	Immacolata Attolico	Received

1326-P	FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA	Juan Manuel Cerezo-Martin	Received

1328-P	SUCCESFUL TREATMENT OF GRAFT FAILURE IN AUTOLOGOUS STEM CELL TRANSPLANTATION WITH CYCLOSPORINE	Damian Cubillas	Received

1329-P	POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.	Francois Dachy	Received

1333-P	PLASMA EXCHANGE, IMMUNOGLOBULIN & PRE-TRANSPLANT IMMUNOSUPPRESSION: AN EFFECTIVE DESENSITISATION STRATEGY FOR DSA ALLOANTIBODIES IN HAPLOIDENTICAL HCT FOR PAEDIATRIC RED CELL DISORDERS	Daniel Dexter	Received

1334-P	THE IMPACT OF IMMUNOSUPPRESSION ON RECONSTITUTION OF CMV-SPECIFIC T CELLS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Anna Dmitrova	Received

1335-P	SECONDARY MALIGNANCIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. SINGLE HOSPITAL EXPERIENCE.	Andrea Dorado López	Received

1342-P	A SCREENING TOOL TO DETECT CHRONIC OCULAR GRAFT VERSUS HOST DISEASE IN A HEMATOLOGY/ ONCOLOGY OUTPATIENT SETTING	Emily Greenan	Received

1343-P	TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR	Ahmet Kursad Gunes	Received

1346-P	EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT	Iman Sulevani	Received

1352-P	THE INTRA-POPULATION HLA DIVERSITY IN CRETE AND THE IMPORTANCE OF THE REGIONAL PUBLIC UMBILICAL CORD BLOOD BANK IN HLA-BASED DONOR SELECTION FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Helen Latsoudis	Received

1356-P	PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	Madlen Jentzsch	Received

1358-P	WILL COVID-19 PANDEMIC CHANGE MOBILIZATION STRATEGY OF HEMATOPOIETIC STEM CELLS IN MULTIPLE MYELOMA PATIENTS FOR THE BETTER?	Bárbara Marques	Received

1359-P	USING GENE-MODIFIED AUTOLOGOUS STEM CELLS PROGENY TO REEDUCATE THE TUMOR IMMUNE MICROENVIRONMENT OF SOLID TUMORS (TEM-GBM STUDY)	Francesca Farina	Received

1362-P	FEASIBILITY OF HAEMATOPOIETIC STEM CELL MOBILIZATION AFTER CONSOLIDATION WITH GEMTUZUMAB OZOGAMICIN AND INTERMEDIATE-DOSES ARA-C AND DAUNORUBICIN IN AML	Salvatore Perrone	Received

1365-P	DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM A RETROSPECTIVE STUDY	D. Rochate	Received

1373-P	TACKLING IMMUNOLOGICAL FINDINGS AS SURROGATE MARKERS OF HISTOLOGICAL SEVERITY AND RESPONSE TO THERAPY IN ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE	Mário Sousa-Pimenta	Received

1380-P	DEGREE OF CELL PACKING OF CRYOPRESERVED AT -80ºC HEMATOPOIETIC STEM CELLS DOES NOT AFFECT THEIR VIABILITY AND HEMATOLOGIC RECOVERY OF TRANSPLANTED MYELOMA PATIENTS	Ivan Tonev	Received

1381-P	EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS	Jule Ussmann	Received

1383-P	EXTRAMEDULLARY RELAPSE OF ACUTE MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A SINGLE-CENTER EXPERIENCE	Francisca Vasconcelos	Received

1386-P	A REVIEW OF HEMATOPOIETIC CELL TRANSPLANTATION IN TAIWAN: DATA AND TRENDS DURING 2009–2018	Yu-Hung Wang	Received

1395-P	POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE-CENTER EXPERIENCE	Suleimen Zhumatayev	Received

1396-P	EFFICACY AND SAFETY COMPARISON OF CALCINEURIN INHIBITORS USED FOR GVHD PROPHYLAXIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA	Suleimen Zhumatayev	Received

1398-P	INSIGHT INTO ACUTE MYELOID LEUKEMIA INDUCED MSC SECRETOME TO REROUTE THE COURSE OF LEUKEMIA BONE MARROW NICHE	Giulia Borella	Received

1405-P	ARGININE-DEPENDENT REGULATION OF THE EUKARYOTIC TRANSLATION INITIATION FACTOR (EIF)5A CONTROLS HUMAN HEMATOPOIETIC PROGENITOR FATE TO THE ERYTHROID LINEAGE	Pedro Gonzalez-Menendez	Received

1406-P	TIMING OF EXPOSURE TO INFECTIOUS MICROBIOTA DETERMINES HSC FITNESS	Jeyan Jayarajan	Received

1408-P	MONOALLELIC AND BIALLELIC GERMLINE MUTATIONS AFFECTING THE TRANSCRIPTION FACTOR HELIOS CAUSE PLEIOTROPIC DEFECTS OF IMMUNITY	Daniel Mayr	Received

1409-P	MACROPHAGES PROVIDE ESSENTIAL SUPPORT FOR ERYTHROPOIESIS DURING CHRONIC PSYCHOLOGICAL STRESS	Sanja Momcilovic	Received

1412-P	UNCOUPLING INK4 PROTEINS FROM CDK4/CDK6 IN HEMATOPOIETIC STEM CELLS	Alessia Schirripa	Received

1420-P	PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES	Beatriz Aranda Orgilles	Received

1421-P	BIMODAL TARGETING OF CYTOKINE RECEPTOR-LIKE FACTOR 2 (CRLF2) WITH JAK INHIBITION AND CHIMERIC ANTIGEN RECEPTOR T CELL IMMUNOTHERAPY IN DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKEMIA	Asen Bagashev	Received

1422-P	IN VIVO G-CSF TREATMENT ACTIVATES THE GR-SOCS1 AXIS TO SUPPRESS IFN-G SECRETION BY NATURAL KILLER CELLS	Xiangyu Zhao	Received

1423-P	CIRCULATING CELL-FREE DNA KINETICS MEASURED BY DIGITAL PCR IN LYMPHOMA PATIENTS UNDERGOING CD19-CAR-T THERAPY	Miguel López-Esteban	Received

1425-P	ACTIVATED AND EXPANDED NATURAL KILLER CELLS TRANSDUCED WITH AN NKG2D CHIMERIC ANTIGEN RECEPTOR AGAINST ACUTE MYELOID LEUKEMIA	Laura Córdoba	Received

1426-P	WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)	Jan Davidson-Moncada	Received

1430-P	GUT MICROBIOTA DIVERSITY AND BUTYRATE PRODUCERS IMPACTS ON NON-HODGKIN LYMPHOMA PATIENTS RESPONSE TO CD19 CAR-T THERAPY	Roberto Garcia-Vicente	Received

1432-P	THE NOVEL DUAL T/B-CELL SIGNALING MOLECULE CONFERS THE GREATER TUMORICIDAL ACTIVITY AND T-CELL PERSISTENCE OF CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL	Wannakorn Khopanlert	Received

1433-P	USE OF A FOAMY-VIRUS VECTOR SYSTEM TO PRODUCE AN ´OFF-THE-SHELF´ ANTI-CD19 CAR T CELL PRODUCT	Ioanna Lazana	Received

1434-P	CORRECTION OF CONGENITAL NEUTROPENIA-RELATED GENES IN NAÏVE IPS CELLS DERIVED FROM PATIENTS USING VIRAL-FREE CRISPR/CAS9 GENE-EDITING SYSTEM	Damian Krzyzanowski	Received

1445-P	MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE	Viktoria Blumenberg	Received

1448-P	LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY	Patrick Derigs	Received

1456-P	EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION	Michael Heuser	Received

1457-P	DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES	Daan Dierickx	Received

1461-P	CAR-T VS. STANDARD OF CARE AS SECOND LINE TREATMENT FOR LARGE B CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Liat Shargian	Received

1462-P	POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE	Anne Mea Spanjaart	Received

1464-P	DECREASING HPK1 EXPRESSION IN CD19 CAR-T CELLS: A NOVEL STRATEGY TO OVERCOME CHALLENGES OF CELL THERAPY FOR ADULT (R/R) B-ALL	Guangxun Gao	Received

1470-P	NATURAL HISTORY AND RATE OF PROGRESSION OF RETINOPATHY IN PATIENTS WITH SICKLE CELL DISEASE: AN 11-YEAR RETROSPECTIVE FOLLOW-UP ANALYSIS	Rajani Brandsen	Received

1471-P	CURRENT INDICATIONS AND RISKS OF SPLENECTOMY IN A LARGE MODERN COHORT OF CHILDREN WITH SCA	Valentine Brousse	Received

1474-P	MOLECURAL MECHANISM OF CHEMOTHERAPEUTIC HYDROXYUREA IS MEDIATED BY NOS2	Teodora Dragojevic	Received

1479-P	A BASELINE AUDIT OF THE USE A VALIDATED PSYCHOMETRIC TOOL (ASCQ-ME) TO ASSESS THE UNMET PSYCHOLOGICAL NEEDS OF A 2021 COHORT OF PATIENTS LIVING WITH SICKLE CELL	Kyle Kelleher	Received

1480-P	SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/?0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY	Joachim Kunz	Received

1492-P	PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS	Minke Rab	Received

1493-P	CHRONIC COMPLICATIONS IN THE EAST LONDON SICKLE NEWBORN COHORT STUDY (ELSNCS)	Muriel Soriano	Received

1494-P	INDICATIONS OF HEMATOPOIETIC STEM CELL TRANSPLANT ACCORDING TO DIFFERENT SETS OF INDICATIONS AND ANALYSIS OF COMORBIDITY INDEX SCORES IN BRAZILIAN PATIENTS WITH SICKLE CELL DISEASE	Gabrielle Santos	Received

1500-P	2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE	S. Van Der Veen	Received

1501-P	FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE	Myrthe J. Van Dijk	Received

1502-P	LONG-TERM FOLLOW-UP OF DUTCH PATIENTS WITH SICKLE CELL DISEASE DIAGNOSED BY NEONATAL SCREENING – EFFECT ON THE MORBIDITY AND MORTALITY IN THE NETHERLANDS.	Caroline Vuong	Received

1503-P	REAL WORLD DATA ON EFFICACY OF PHARMACEUTICAL-GRADE L-GLUTAMINE IN PREVENTING SICKLE CELL DISEASE-RELATED ACUTE COMPLICATIONS AND HEMOLYSIS IN PEDIATRIC AND ADULT PATIENTS.	Mohamed Yassin	Received

1504-P	AN AUDIT OF PAIN EDUCATION IN PATIENTS WITH SICKLE CELL DISEASE	Yuhui Zhou	Received

1505-P	USING ARTIFICIAL INTELLIGENCE NEURAL NETWORKS TO OBTAIN AUTOMATED LIVER IRON CONCENTRATION MEASUREMENTS USING MAGNETIC RESONANCE IMAGING – A MULTI-SCANNER VALIDATION STUDY	Tim St Pierre	Received

1506-P	REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA	Polyxeni Delaporta	Received

1511-P	EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH ?-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW	Antonio Piga	Received

1512-P	HEART FAILURE IN THALASSEMIA MAJOR: TIME FOR NEW CARDIOVASCULAR MAGNETIC RESONCE MARKERS?	Antonella Meloni	Received

1513-P	LOW VITAMIN D LEVELS ARE ASSOCIATED WITH INCREASED CARDIAC IRON UPTAKE IN THALASSEMIA MAJOR.	Antonella Meloni	Received

1514-P	MULTI-PARAMETRIC CARDIAC MAGNETIC RESONANCE FOR RISK PREDICTION OF HEART FAILURE DEATH IN THALASSEMIA MAJOR	Antonella Meloni	Received

1515-P	IMPACT OF GENOTYPE ON PANCREATIC IRON OVERLOAD AND IMPAIRED GLUCOSE METABOLISM IN THALASSEMIA MAJOR	Antonella Meloni	Received

1525-P	MANAGEMENT OF AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING PREGNANCY OR POST-PARTUM: AN INTERNATIONAL MULTI-CENTRE EXPERIENCE.	Marta Bortolotti	Received

1526-P	AUTOIMMUNE HEMOLYTIC ANEMIAS: RELATIONSHIP BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS OF CYTOKINE GENES AND CLINICAL/HEMATOLOGICAL PARAMETERS	Bruno Fattizzo	Received

1527-P	NEXT GENERATION SEQUENCING IN HEREDITARY SPHEROCYTOSIS DIAGNOSIS	Ana García Feria	Received

1529-P	HEMOGLOBIN RESPONSE TO ZINC SUPPLEMENTATION IN PATIENTS WITH ZINC DEFICIENCY AND CHRONIC ANEMIA	Zachary Hanson	Received

1530-P	PERITRANFUSIONAL C1-INHIBITOR IN PATIENTS WITH SEVERE COMPLEMENT-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA: AN OPEN LABEL PHASE 2 TRIAL.	Marit Jalink	Received

1531-P	HETEROGENEITY OF DISEASE-CAUSING GENOTYPES BETWEEN FAMILIES WITH HEREDITARY SPHEROCYTOSIS: A SINGLE-CENTER COHORT STUDY	Raul Jimenez Heredia	Received

1537-P	HEREDITARY ANEMIA CAUSED BY MULTILOCUS INHERITANCE OF PIEZO1, SLC4A1 AND ABCB6 MUTATIONS: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE.	Barbara Eleni Rosato	Received

1540-P	STUDY OF MIRNA EXPRESSION PROFILES IN GAUCHER PATIENTS AND THEIR RELATIONSHIP WITH THE SEVERITY OF BONE INVOLVEMENT	Irene Serrano-Gonzalo	Received

1541-P	PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT.	Irene Serrano-Gonzalo	Received

1549-P	NOVEL SLC4A1 GENE MUTATIONS IN HEREDITARY SPHEROCYTOSIS BAND 3 PROTEIN-DEFICIENT TUNISIAN PATIENTS	Nawel Trabelsi	Received

1552-P	A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION	Ulrich Jaeger	Received

1554-P	INCREASED PREVALENCE OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE I	Mahdi Asleh	Received

1555-P	IRON CHELATION THERAPY IN CONGENITAL HEMOLYTIC ANEMIAS: AN ITALIAN SINGLE CENTER STUDY	Alessandro Bosi	Received

1559-P	DISC-0974, A FIRST-IN-HUMAN ANTI-HEMOJUVELIN MONOCLONAL ANTIBODY, REDUCES SERUM HEPCIDIN LEVELS AND MOBILIZES IRON IN HEALTHY PARTICIPANTS	Will Savage, Md, Phd	Received

1560-P	IMR-261, A NOVEL, ORAL NRF2 ACTIVATOR, REDUCES IRON OVERLOAD IN AN EXPERIMENTAL MOUSE MODEL BY ACTIVATING BMP6-MEDIATED HEPCIDIN SYNTHESIS	Thiago Trovati Maciel	Received

1561-P	IS IRON OVERLOAD ASSOCIATED WITH WORSE OUTCOMES IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING LIVER TRANSPLANT?	Sergio Rodriguez-Rodriguez	Received

1566-P	PROTON PUMP INHIBITION FOR SECONDARY HEMOCHROMATOSIS IN HEREDITARY ANEMIA, A PHASE III PLACEBO-CONTROLLED RANDOMIZED CROSS-OVER CLINICAL TRIAL	A.J. Van Vuren	Received

1568-P	EARLY, BUT NOT LATE USE OF REMDESVIR AND CONVALESCENT PLASMA REDUCES MORTALITY OF COVID 19 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES – A STUDY OF KROHEM	Igor Aurer	Received

1569-P	COVID19 AND ITS IMPACT ON HEMATO-ONCOLOGICAL PATIENTS. DIFFERENCES IN OUTCOMES IN RELATION TO OMICRON CIRCULATION AND VACCINATION STATUS?	Matilde Boada	Received

1571-P	EVALUATION OF THE CLINICAL IMPACT OF BONE MARROW CULTURES IN CURRENT MEDICAL PRACTICE	Gal Sharvit	Received

1577-P	RISK FACTORS FOR MORTALITY IN CRITICALLY ILL PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A POLYVALENT INTENSIVE CARE UNIT: A RETROSPECTIVE STUDY	Ana Raquel Dias	Received

1584-P	CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS	Ronit Gurion	Received

1587-P	IS IT SAFE FOR OUR PATIENTS TO COME OUT?	Magda Jabbar Al-Obaidi	Received

1588-P	A SINGLE CENTER COMPARATIVE CLINICAL ANALYSIS OF THE SARS-COV-2 INFECTION BEFORE AND AFTER VACCINATION IN PATIENTS DIAGNOSED WITH HEMATOLOGIC MALIGNANCIES	Moraima Jiménez	Received

1591-P	HIGH RISK OF BLOOD STREAM INFECTION OF CRE CARRIERS IN NEUTROPENIC CHILDREN WITH HEMATOLOGICAL DISEASES	Li-Peng Liu	Received

1596-P	PREDIAGNOSTIC ANTIMICROBIAL USE IN CLL, MM, FL AND DLBCL	Esben Munk Packness	Received

1597-P	THE DYNAMIC INTERACTION BETWEEN INFLAMMATION AND IRON SENSORS IN MALARIA-INDUCED ANEMIA	Ana Pêgo	Received

1601-P	THE ASSESSMENT OF PREDICTIVE ROLE OF PROTEIN C AND S FOR CRITICAL FORM OF COVID-19	Viola Popov	Received

1602-P	THE ASSESSMENT OF LYMPHOPENIA AS RISK FACTOR FOR UNFAVORABLE EVOLUTION OF PATIENTS WITH SEVERE FORM OF COVID 19	Viola Popov	Received

1605-P	OUTCOME OF SARS-COV-2 INFECTION IN HAEMATOLOGICAL CANCER PATIENTS (PTS) IN TWO DIFFERENT PANDEMIC PHASES AT A SINGLE CENTRE	Raquel Rodrigues	Received

1606-P	CENTRAL VEIN CATHETERISATION IN ONCOHEMATOLOGICAL PATIENTS: COMPLICATION, ASSOCIATED WITH PROCEDURA AND CARE	Nikolay Romanenko	Received

1607-P	EPICOVIDEHA KIDS: A READY TO USE PLATFORM FOR EPIDEMIOLOGICAL STUDIES IN PEDIATRIC HEMATOLOGICAL PATIENTS WITH COVID-19	Jon Salmanton-García	Received

1608-P	EXPERIENCE AND COMPLICATIONS WITH THE USE OF PICCS IN HEMATOLOGIC PATIENTS	Laura Sanchez-Paz	Received

1609-P	VERY LOW MORTALITY IN DOUBLE VACCINATED IMMUNOCOMPROMISED HAEMATOLOGY PATIENTS INFECTED WITH SARS-COV-2.	Briony Shaw	Received

1610-P	IMPACT OF COVID-19 ON PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE COHORT STUDY	Thomas Silfverberg	Received

1614-P	MOLECULAR EPIDEMIOLOGY OF INFLUENZA VIRUS IN PATIENTS WITH HEMATOLOGIC DISORDERS	Silan Ünal	Received

1618-P	CLINICAL OUTCOME OF COVID-19 CONVALESCENT PLASMA TRANSFUSION IN CHRONIC KIDNEY DISEASE PATIENTS ON RENAL REPLACEMENT THERAPY WITH SEVERE TO CRITICAL COVID-19 DISEASE	Janelle Ahorro	Received

1622-P	ANTIPHOSPHOLIPID ANTIBODIES IN CONVALESCENT PLASMA OF DONORS RECOVERED FROM MILD COVID-19	Dorit Blickstein	Received

1626-P	MANAGEMENT OF POST-TRANSFUSION COMPLICATIONS IN PATIENTS WITH HEMATOLOGICAL DISEASES. PREVENTION IS BETTER THAN CURE–DATA FROM A SINGLE INSTITUTION	Yonka Lazarova	Received

1627-P	EXPERIENCE OF THE USE OF CONVALESCENT PLASMA FOR THE MANAGEMENT OF COVID 19 IN PATIENTS WHO REQUIRED HOSPITALIZATION IN QUITO-ECUADOR, HOSPITAL METROPOLITANO, DURING THE 2020 PERIOD	Johanna Rojas	Received

1629-P	ADMINISTRATION OF CONVALESCENT PLASMA FOR THE TREATMENT OF SEVERE COVID-19: RESULTS OF A MULTICENTER PHASE II TRIAL	Thomas Thomopoulos	Received

1632-P	PROSPECTIVE OBSERVATIONAL STUDY IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) TREATED WITH TPO-R AGONISTS (TPO-RA): ELTROMBOPAG (EPAG) AND ROMIPLOSTIM (ROMI) - THE PEPITE STUDY	Stéphane Chèze	Received

1636-P	PATIENT PREFERENCES AND EXPERIENCES REGARDING THROMBOPOIETIN-RECEPTOR AGONISTS FOR IMMUNE THROMBOCYTOPENIA IN THE NETHERLANDS (TRAPEZE NL STUDY).	A.J. Gerard Jansen	Received

1639-P	UTILITY OF NEXT GENERATION SEQUENCING TECHNIQUES TO EVALUATE POSSIBLE CAUSES OF REFRACTORINESS TO TREATMENT WITH ELTROMBOPAG IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN SPAIN.	Tomas Jose Gonzalez-Lopez	Received

1644-P	NOVEL VARIANTS IN GALE CAUSED SYNDROMIC MACROTHROMBOCYTOPENIA DISRUPTING THROMBOPOIESIS AND GLYCOSYLATION	Ana Marin Quilez	Received

1647-P	CONTRIBUTION OF NEXT GENERATION FLOW (NGF) CYTOMETRY IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UTILITY FOR THE DIFFERENTIAL DIAGNOSIS WITH MYELODYSPLASTIC SYNDROMES	Tomas Jose Gonzalez-Lopez	Received

1649-P	GFI1B AND LSD1 REPRESS A MYELOID DIFFERENTIATION PROGRAM DURING INDUCED PLURIPOTENT STEM CELL DERIVED MEGAKARYOCYTE DIFFERENTIATION	Jeron Venhuizen	Received

1653-P	CLINICAL EFFICACY AND SAFETY OF SWITCHING ELTROMBOPAG AND RH-TPO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA DURING THE COVID-19 PANDEMIC	Xuan Cai	Received

1659-P	UNIQUE GENOTYPE-PHENOTYPE RELATIONSHIP IN VON WILLEBRAND DISEASE: A SINGLE CENTRE EXPERIENCE	Mohamed Elshinawy	Received

1663-P	THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA	Oliver Königsbrügge	Received

1664-P	IMPACT OF A PROTOCOL USING RITUXIMAB FOR PREVENTION OF RELAPSE IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP)	Elena Marín Sánchez	Received

1669-P	AUTOANTIBODY-MEDIATED PLATELET DESIALYLATION IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA	Theresa Schramm	Received

1673-P	THROMBOTIC COMPLICATIONS IN MERS-COV COMPARED TO COVID-19	Abdulrahman Al Raizah	Received

1674-P	CLINICAL IMPACT OF NON-ADHERENCE TO HIT GUIDELINES: A DOUBLE HIT IN HIT	Abdulrahman Al Raizah	Received

1681-P	FXI LEVELS AS INDEPENDENT RISK FACTOR FOR THROMBOSIS/OBSTETRIC EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES	María Eugenia De La Morena-Barrio	Received

1682-P	MTHFR C677T GENOTYPE IN CORRELATION WITH THROMBOSIS AND ASSOCIATION WITH FVIII COAGULANT ACTIVITY IN GREEK PAEDIATRIC POPULATION	Athina Dettoraki	Received

1684-P	NO INCREASE IN THROMBIN GENERATION OR D-DIMER LEVELS AFTER ANTI-SARS-COV-2 VACCINES INCLUDING IN THOSE WITH ANTI-PLATELET FACTOR 4 ANTIBODIES	Lamya Garabet	Received

1690-P	NEUTROPHIL EXTRACELLULAR TRAP (NET) LEVELS IN COVID-19 PATIENTS	Laura López De Frutos	Received

1692-P	PREDICTIVE MODEL FOR VEIN THROMBOEMBOLIC EVENTS DEVELOPMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Mirjana Mitrovic	Received

1693-P	THROMBOMODULIN RESISTANCE: A NEW PROTHROMBOTIC PATHWAY IN COVID-19	Adrián Montaño	Received

1695-P	CEREBRAL VENOUS THROMBOSIS AND ANTITHROMBOTIC THERAPY: A SYSTEMATIC REVIEW	Vaia Papageorgiou	Received

1697-P	EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF THE TINA-QUANT D-DIMER GEN. 2 IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS	Brita Tonne	Received

1698-P	INCREASED COMPLEMENT ACTIVATION AND DECREASED ADAMTS13 ACTIVITY IN PATIENTS WITH PRE-ECLAMPSIA COMPARED TO HEALTHY PREGNANCIES	Theodora Maria Venou	Received

1701-P	A COMPARATIVE STUDY OF THE IMPACT OF COUNTRIES´ HEALTH EXPENDITURE ON THE DIAGNOSIS EXPERIENCES OF PATIENTS WITH LYMPHOMA AND CLL IN EUROPE	Funmi Bamigbola	Received

1702-P	IMPACT OF CENTER CHARACTERISTICS AND MACROECONOMIC FACTORS ON THE OUTCOME OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC-INSPIRED PROTOCOLS	Pere Barba	Received

1706-P	CLINICAL UTILITY OF ONLINE MONITORING OF PATIENT-REPORTED SYMPTOMS IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN REAL-LIFE PRACTICE	Fabio Efficace	Received

1708-P	PREGNANCIES IN YOUNG ADULTS WITH A HISTORY OF ACUTE LYMPHOBLASTIC LEUKEMIA IN ITALY. A CAMPUS ALL SURVEY.	Fabio Giglio	Received

1709-P	FERTILITY PRESERVATION FOR YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIAS IN ITALY: A CAMPUS ALL SURVEY.	Fabio Giglio	Received

1716-P	REGULAR HOSPITAL VISITS IMPROVE THE PROGNOSIS OF MULTIPLE MYELOMA PATIENTS	Xiaozhe Li	Received

1718-P	A PROSPECTIVE MULTICENTER SURVEY ABOUT THE USE OF NEW TECHOLOGIES AND DIGITAL HEALTH TOOLS IN PATIENTS (PTS) WITH HEMATOLOGICAL MALIGNANCIES	Alberto Lopez-Garcia	Received

1719-P	A PATIENT ADVOCACY PERSPECTIVE ABOUT CHRONIC MYELOID LEUKEMIA INEQUITIES IN ACCESS TO THERAPIES AND PATIENT JOURNEY IN THE LATIN AMERICAN REGION.	Jose Luis Castro Aguilar	Received

1721-P	PROGNOSTIC FACTORS IN PATIENTS IN THE TERMINAL PHASE OF HEMATOLOGICAL MALIGNANCIES WHO RECEIVED HOME MEDICAL CARE	Naohiro Miyashita	Received

1725-P	OBSERVATIONAL STUDY TO EVALUATE PATIENT-REPORTED OUTCOMES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Esther Natalie Oliva	Received

1728-P	THE FUTURE OF MYELODYSPLASTIC SYNDROME – PATIENT PRIORITIES AND OUTCOMES THAT MATTER	Matthew Poynton	Received

1729-P	COMPARING THE PSYCHOSOCIAL IMPACTS OF THE COVID-19 PANDEMIC BETWEEN HAEMATOLOGICAL CANCER AND MYELOMA PATIENTS: FINDINGS FROM AN ONLINE SURVEY	Stephen James Quinn	Received

1730-P	IMPLEMENTATION OF PRO-CTCAE QUESTIONNAIRE IN PROM PROGRAM COLLECTS DIFFERENT ADVERSE EVENTS PROFILE THAN PHYSICIANS AND REDUCE UNSCHEDULED HEALTHCARE IN PATIENTS WITH LYMPHOMA RECEIVING IV THERAPY	Sergio Ramos	Received

1733-P	NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET	Sudipto Mukherjee	Received

1734-P	LESSONS FROM HIV- HAEMOPHILIA CRISIS AND CURRICULAR LEARNING IN POST COVID TIMES	Mallika Sekhar	Received

1746-P	LONG-TERM NON-HODGKIN LYMPHOMA SURVIVORS IN CÔTE D´OR: HEALTH-RELATED QUALITY OF LIFE AND LIVING CONDITIONS.	Stephane Wasse	Received

EHA2022 Hybrid Congress

June 9-12 Vienna

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 09/06/2022 TO 09/06/2022

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access